Mödder U I, Sanyal A, Xu J, O'Malley B W, Spelsberg T C, Khosla S
Endocrine Research Unit, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Bone. 2008 Feb;42(2):414-21. doi: 10.1016/j.bone.2007.10.017. Epub 2007 Nov 4.
Estrogen (E) is critical for the maintenance of bone mass in both female and male mice and steroid receptor coactivator (SRC)-1 has been shown to be important for mediating E effects on bone, at least in female mice. In the present study, we defined the skeletal phenotype of male SRC-1 knock out (KO) mice and compared it with their female littermates. Further, to determine the role of SRC-1 in mediating effects of E on bone in male mice, we examined the skeletal effects of gonadectomy (gnx) with or without E replacement in male mice and placed these findings in the context of our previous studies in female SRC-1 KO mice. Analysis of a large group of male (WT, n=67; SRC-1 KO, n=56) and female (WT, n=66; SRC-1 KO, n=70) mice showed a significant decrease in trabecular volumetric bone mineral density (vBMD) in SRC-1 KO mice compared to their WT littermates in both genders (male SRC-1 KO, 275+/-3 vs. WT, 295+/-3 mg/cm(3), P<0.001; female SRC-1 KO, 210+/-2 vs. WT, 221+/-2 mg/cm(3), P<0.001). Following gnx and E replacement (10 microg/kg/day), we previously demonstrated that SRC-1 KO female mice have a defect in E action in trabecular, but not in cortical bone. In contrast, we now demonstrate that the same dose of E administered to gnx'd male SRC-1 KO mice was sufficient to prevent trabecular bone loss in these mice. For example, in WT female mice, gnx followed by E replacement maintained spine BMD (1.2+/-3.4% vs. baseline) as compared to gnx without E replacement (-12.7+/-2.6%, P<0.001 vs. sham); this effect of E was absent in SRC-1 KO female mice. By contrast, the identical dose of E was equally effective in maintaining spine BMD in E-treated gnx'd male WT (-5.2+/-5.1% vs. baseline) and male SRC-1 KO (-5.4+/-5.3%) mice, respectively, as compared to gnx'd mice without E treatment (WT, -17.6+/-2.5%, P=0.02; SRC-1 KO, -28.6+/-2.6%, P<0.001 vs. sham). E treatment was effective in suppressing cancellous bone turnover in both gnx'd WT and SRC-1 KO male mice as determined by significant reductions in osteoblast and osteoclast numbers; however, in female mice, E treatment only suppressed bone turnover in WT but not in SRC-1 KO mice. Collectively, these findings demonstrate that loss of SRC-1 results in trabecular osteopenia in male and female mice, but in contrast to female mice, this is not due to any detectable resistance to E action in trabecular bone in male SRC-1 KO mice.
雌激素(E)对于维持雌性和雄性小鼠的骨量都至关重要,并且类固醇受体辅激活因子(SRC)-1已被证明对于介导E对骨骼的作用很重要,至少在雌性小鼠中是这样。在本研究中,我们确定了雄性SRC-1基因敲除(KO)小鼠的骨骼表型,并将其与其雌性同窝小鼠进行比较。此外,为了确定SRC-1在介导E对雄性小鼠骨骼作用中的作用,我们研究了去势(gnx)且有或没有E替代的雄性小鼠的骨骼效应,并将这些发现与我们之前在雌性SRC-1 KO小鼠中的研究结果相结合。对一大组雄性(野生型,n = 67;SRC-1 KO,n = 56)和雌性(野生型,n = 66;SRC-1 KO,n = 70)小鼠的分析表明,与它们的野生型同窝小鼠相比,SRC-1 KO小鼠的小梁体积骨密度(vBMD)显著降低(雄性SRC-1 KO,275±3 vs.野生型,295±3 mg/cm³,P<0.001;雌性SRC-1 KO,210±2 vs.野生型,221±2 mg/cm³,P<0.001)。在去势和E替代(10μg/kg/天)后,我们之前证明SRC-1 KO雌性小鼠在小梁骨中存在E作用缺陷,但在皮质骨中没有。相比之下,我们现在证明给予去势的雄性SRC-1 KO小鼠相同剂量的E足以防止这些小鼠的小梁骨丢失。例如,在野生型雌性小鼠中,去势后进行E替代可维持脊柱骨密度(与基线相比为1.2±3.4%),而去势后不进行E替代则会降低(-12.7±2.6%,与假手术组相比P<0.001);SRC-1 KO雌性小鼠中没有E的这种作用。相比之下,相同剂量的E在维持接受E治疗的去势雄性野生型(与基线相比为-5.2±5.1%)和雄性SRC-1 KO(-5.4±5.3%)小鼠的脊柱骨密度方面同样有效,而去势后未接受E治疗的小鼠(野生型,-17.6±2.5%,P = 0.02;SRC-1 KO,-28.6±2.6%,与假手术组相比P<0.001)。E治疗在抑制去势的野生型和SRC-1 KO雄性小鼠的松质骨转换方面有效,这通过成骨细胞和破骨细胞数量的显著减少来确定;然而,在雌性小鼠中,E治疗仅抑制野生型小鼠的骨转换,而不抑制SRC-1 KO小鼠的骨转换。总的来说,这些发现表明SRC-1的缺失导致雄性和雌性小鼠出现小梁骨减少,但与雌性小鼠不同的是,这并不是由于雄性SRC-1 KO小鼠的小梁骨中对E作用存在任何可检测到的抵抗。